Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Analysts

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been given an average recommendation of “Buy” by the ten ratings firms that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $11.50.

CATX has been the subject of several recent analyst reports. UBS Group reaffirmed a “buy” rating and issued a $7.00 target price (down previously from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. B. Riley reduced their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research note on Friday, October 3rd. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, November 11th. Finally, BTIG Research initiated coverage on shares of Perspective Therapeutics in a report on Friday, October 10th. They set a “buy” rating and a $14.00 price target for the company.

Perspective Therapeutics Stock Performance

CATX stock opened at $2.52 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $5.39. The company’s 50 day simple moving average is $2.88 and its 200-day simple moving average is $3.30.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%.The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million. On average, equities research analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Nuveen LLC bought a new stake in Perspective Therapeutics during the first quarter worth approximately $2,647,000. Affinity Asset Advisors LLC raised its position in shares of Perspective Therapeutics by 71.1% in the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock valued at $4,738,000 after purchasing an additional 924,196 shares during the period. Bank of America Corp DE lifted its stake in shares of Perspective Therapeutics by 139.9% in the third quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock worth $2,695,000 after buying an additional 458,323 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Perspective Therapeutics by 118.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after buying an additional 405,612 shares during the period. Finally, Patient Square Capital LP acquired a new position in Perspective Therapeutics in the 3rd quarter valued at $1,198,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.